Stock ARWR ARROWHEAD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
24.13 USD +4.14% Intraday chart for Arrowhead Pharmaceuticals, Inc. +10.33% -21.14%
04-24 Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease CI
04-07 Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Arrowhead Pharmaceuticals, Inc. Appoints Hongbo Lu as Independent Director, Effective April 1, 2024
Sector Update: Health Care Stocks Firmer Late Afternoon
Sector Update: Health Care Stocks Advance in Afternoon Trading
Sector Update: Health Care Stocks Mixed Premarket Wednesday
Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,860,019, According to a Recent SEC Filing
Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024
Arrowhead Pharmaceuticals Insider Sold Shares Worth $292,804, According to a Recent SEC Filing
Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,910, According to a Recent SEC Filing
Arrowhead Pharmaceuticals Shares Rise as $450 Million Underwritten Share Offering Priced
Arrowhead Pharmaceuticals Prices $450 Million Underwritten Share Offering
Arrowhead Pharmaceuticals Insider Sold Shares Worth $342,480, According to a Recent SEC Filing
Arrowhead Pharmaceuticals' Fiscal 2023 Net Loss Widens, Revenue Falls
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARWR Stock
  4. News Arrowhead Pharmaceuticals, Inc.
  5. Other languages